Is StageZero Life Sciences Ltd. (SZLSF) a Buy, Sell, or Hold?
OTC : SZLSF
StageZero Life Sciences Ltd.
$0.001 USD
$0 (0.0%)
- Volume
- 300
- Average Volume
- 7
- Market Capitalization
- $123.53K
- P/E Ratio
- -0.01
- Dividend Yield
- 0.00%
- Price Target
- Year High
- $0.02
- Year Low
- $0.00
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $0.04
Company Overview
OTC
James R. Howard-Tripp
Medical - Diagnostics & Research
Healthcare
SZLSF
40
CA
USD
Liquidity Metrics
-0.24
0.04
0.02
0.00
0.00
Sales & Valuation
$3.8M
0.03
-0.01
-0.04
-0.04
Profitability
-$0.11
-$11.42M
-300.79%
-300.79%
481.50%
-1629.25%
P/E Metrics
-0.01
0.00
0.00
Analyst Price Target & Rating
0/5
0 Analysts
%
Financial Health Scores
-336.37
2/9
-$10.09M
$580.75K
$11.71M
-$2.08M
Key Metrics (TTM)
$1.91M
0.50
-0.19
0.04
481.50%
151.84%
-11481.22%
-2856.53%
-234 days
Company Executives
| Name | Title |
|---|---|
| James R. Howard-Tripp | Executive Chairman & Chief Executive Officer |
| Choong-Chin Liew | Co-Founder |
| Warren Whitehead | Chief Accountant |
Poll Results
No votes yet today — be the first to share your view!
About StageZero Life Sciences Ltd. (OTC:SZLSF) Stock
StageZero Life Sciences Ltd. is a vertically integrated healthcare enterprise focused on the development and commercialization of proprietary molecular diagnostic tests. These tests are primarily designed for the early detection of diseases and to facilitate personalized health management, with a particular emphasis on oncology-related conditions within the United States and Canada. At the core of their offerings is the proprietary Sentinel Principle platform technology, which specializes in identifying novel biomarkers from whole blood samples. The company's lead product, Aristotle, is an innovative multi-cancer panel test capable of simultaneously screening for numerous cancer types from a single blood sample, demonstrating high sensitivity and specificity for each detected cancer. Stage ... Zero's product portfolio also encompasses ColonSentry, a blood test that assesses an individual's current risk of colorectal cancer; COVID-19 polymerase chain reaction (PCR) testing and detailed blood test analysis; the Prostate Health Index, a screening tool for prostate cancer; and BreastSentry, a test designed to determine a woman's risk of developing breast cancer. Established in 1998, the company maintains its headquarters in Richmond Hill, Canada.
Frequently Asked Questions
-
What is the current StageZero Life Sciences Ltd. (SZLSF) stock price?
-
StageZero Life Sciences Ltd.(OTC:SZLSF) stock price is $0.001 in the last trading session. During the trading session, SZLSF stock reached the peak price of $0.0215 while $0.0005 was the lowest point it dropped to. The percentage change in SZLSF stock occurred in the recent session was 0.0% while the dollar amount for the price change in SZLSF stock was $0.
-
SZLSF's industry and sector of operation?
-
The OTC listed SZLSF is part of Medical - Diagnostics & Research industry that operates in the broader Healthcare sector.
-
Who are the executives of SZLSF?
-
James R. Howard-Tripp | Executive Chairman & Chief Executive Officer
Choong-Chin Liew | Co-Founder
Warren Whitehead | Chief Accountant
|
| -
How many employees does SZLSF have?
-
Number of SZLSF employees currently stands at 40. SZLSF operates from 70 East Beaver Creek Road, Richmond Hill, ON L4B 3B2, CA.
-
Link for SZLSF official website?
-
Official Website of SZLSF is: https://www.stagezerolifesciences.com
-
How do I contact SZLSF?
-
SZLSF could be contacted at phone #+1 804 261 3340 and can also be accessed through its website. SZLSF operates from 70 East Beaver Creek Road, Richmond Hill, ON L4B 3B2, CA.
-
How many shares of SZLSF are traded daily?
-
The average number of SZLSF shares traded daily for last 3 months was 7.
-
What is the market cap of SZLSF currently?
-
The market value of SZLSF currently stands at $123.53K with its latest stock price at $0.001